

VEDOLIZUMAB AS RESCUE THERAPY FOR ACUTE SEVERE ULCERATIVE COLITIS INDUCED BY SECOND-LINE CHEMOTHERAPY FOR RECURRENCE OF PLEOMORPHIC LUNG CARCINOMA

Giusi Arboretto

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A case report describes successful use of Vedolizumab as rescue therapy in a patient with acute severe ulcerative colitis when Infliximab was contraindicated due to oncologic history.

KEY POINTS

- A 56-year-old male with steroid-dependent ulcerative colitis developed acute severe UC induced by chemotherapy for recurrent lung carcinoma; Infliximab rescue therapy was contraindicated due to his cancer history and colectomy was also contraindicated.
- After administration of Vedolizumab 300 mg, bowel movements reduced significantly starting the day after infusion, normalized within three days, and inflammatory indices normalized concomitantly.
- The patient achieved clinical remission and continues maintenance therapy with Vedolizumab 108 mg subcutaneously every two weeks.
- The authors suggest this case demonstrates Vedolizumab may be a potential rescue therapy option in acute severe UC for special populations where it may offer a better safety profile, though current guidelines lack significant recommendations on this use.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/20de3d28-743c-11ee-9c82-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.